CASI: 凯信远达

CASI新闻

• 03:03 What Drove CASI Pharmaceuticals' 24% Rise After Hours? - CASI Pharmaceuticals (NASDAQ:CASI)
• 21:30 U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
• 21:30 美国股市上涨；截至收盘道琼斯工业平均指数上涨0.63%
• 18:31 CASI Pharmaceuticals因纳斯达克摘牌通知股价暴跌
• 18:30 CASI Pharmaceuticals stock plunges on Nasdaq delisting notice
• 14:40 Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
• 14:40 Are Medical Stocks Lagging Alkermes (ALKS) This Year?
• 14:21 中国批准凯赛制药的CID-103用于肾脏排斥反应的临床试验
• 14:14 China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection
• 21:18 CASI制药公司获纳斯达克延期上市许可后股价飙升
• 21:17 CASI制药获纳斯达克延期上市至2026年2月
• 21:16 CASI Pharmaceuticals stock surges after Nasdaq grants listing extension
• 21:13 Casi Pharmaceuticals secures Nasdaq listing extension until February 2026
• 14:17 CASI Pharmaceuticals secures $20 million funding for transplant rejection study
• 14:09 CASI Pharmaceuticals reports positive phase 1 data for ITP treatment
• 21:30 CASI制药因市值要求面临纳斯达克摘牌风险
• 21:26 CASI Pharmaceuticals faces Nasdaq delisting over market value requirement
• 13:55 黄晶将加入CASI制药董事会担任独立董事
• 13:54 James Huang to join CASI Pharmaceuticals board as independent director
• 13:13 CASI Pharmaceuticals advances anti-CD38 antibody in ITP trial
• 21:20 Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates
• 10:51 Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Advent Technologies Hldgs (NASDAQ:ADN), Adaptimmune Therapeutics (NASDAQ:ADAP)
• 13:15 VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
• 21:25 VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates